CGTX - Cognition Therapeutics, Inc. Stock Price, Fair Value and News

$0.440.00 (0.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CGTX Price Action

Last 7 days

-18.5%

Last 30 days

-6.4%

Last 90 days

-42.1%

Trailing 12 Months

-56.0%

CGTX RSI Chart

CGTX Valuation

Market Cap

18.3M

Price/Earnings (Trailing)

-0.53

Price/Sales (Trailing)

0.77

EV/EBITDA

-0.02

Price/Free Cashflow

-0.87

CGTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CGTX Fundamentals

CGTX Revenue

Revenue (TTM)

23.7M

Rev. Growth (Yr)

-44.13%

Rev. Growth (Qtr)

-12.6%

CGTX Earnings

Earnings (TTM)

-34.3M

Earnings Growth (Yr)

-47.24%

Earnings Growth (Qtr)

-41.13%

CGTX Profitability

EBT Margin

-86.60%

Return on Equity

-236.64%

Return on Assets

-124.26%

Free Cashflow Yield

-114.53%

CGTX Investor Care

Shares Dilution (1Y)

36.59%

Diluted EPS (TTM)

-0.97

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	22.8M	0	23.7M	0
2023	19.7M	0	21.0M	21.9M
2022	18.7M	20.4M	23.3M	22.2M
2021	12.5M	14.2M	15.8M	17.4M
2020	0	0	0	10.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.

CEO	Ms. Lisa Ricciardi
WEBSITE	cogrx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	22

Cognition Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Cognition Therapeutics, Inc.? What does CGTX stand for in stocks?

CGTX is the stock ticker symbol of Cognition Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cognition Therapeutics, Inc. (CGTX)?

As of Wed Nov 20 2024, market cap of Cognition Therapeutics, Inc. is 18.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CGTX stock?

You can check CGTX's fair value in chart for subscribers.

Is Cognition Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether CGTX is over valued or under valued. Whether Cognition Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Cognition Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CGTX.

What is Cognition Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, CGTX's PE ratio (Price to Earnings) is -0.53 and Price to Sales (PS) ratio is 0.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CGTX PE ratio will change depending on the future growth rate expectations of investors.